Amniotomy plus intravenous oxytocin for induction of labour
A Cochrane review 1 included 17 trials involving 2,566 women. In a single study of 100 women amniotomy and intravenous oxytocin resulted in fewer women being undelivered vaginally at 24 hours than amniotomy alone (RR 0.03, 95% CI 0.001–0.49). Amniotomy and intravenous oxytocin resulted in significantly fewer instrumental vaginal deliveries than placebo (RR 0.18, 95% CI 0.05–0.58). In two studies comparing amniotomy and oxytocin with vaginal PGs (amniotomy or oxytocin was added to PGs in case of no spontaneous labour) there were more postpartum haemorrhage (13.75% vs 2.5%, RR 5.5, 95% CI 1.26–24.07, 160 women).
A network meta-analysis 2 assessed the relative effectiveness, safety and cost-effectiveness of labour induction methods. 611 trials were included. The interventions most likely to achieve vaginal delivery within 24 hours were intravenous oxytocin with amniotomy (posterior rank 2; 95% credible intervals (CI) 1 to 9) and higher-dose (≥ 50 µg) vaginal misoprostol (rank 3; 95% CI 1 to 6) (table T1). Compared with placebo, several treatments reduced the odds of caesarean section, but there were considerable uncertainty in treatment rankings. For uterine hyperstimulation, double-balloon catheter had the highest probability of being among the best 3 treatments, whereas vaginal misoprostol (≥ 50 µg) was most likely to increase the odds of excessive uterine activity.
Table 1. Interventions for failure to achieve vaginal delivery within 24 hours
|Active intervention vs placebo||Odds ratio||95% CI|
|i.v. oxytocin with amniotomy||0.05||0.07 to 0.32|
|Vaginal misoprostol ≥ 50 μg||0.09||0.06 to 0.24|
|Titrated (low-dose) oral misoprostol solution||0.10||0.07 to 0.29|
|Vaginal misoprostol < 50 μg||0.11||0.09 to 0.32|
|Buccal/sublingual misoprostol||0.11||0.05 to 0.19|
|Vaginal PGE2 pessary (normal release)||0.11||0.04 to 0.16|
|Oral misoprostol tablet ≥ 50 μg||0.16||0.05 to 0.20|
|Double-balloon or Cook’s catheter||0.18||0.01 to 0.16|
|Foley catheter||0.19||0.09 to 0.46|
|Oral misoprostol tablet < 50 μg||0.22||0.07 to 0.39|
Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison) and by indirectness (no single study addressed all the primary outcomes).
Copyright © 2022 Duodecim Medical Publications Limited.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.